Organon & Co. (NYSE:OGN – Get Free Report)’s share price reached a new 52-week high during trading on Monday. The stock traded as high as $13.91 and last traded at $13.9050, with a volume of 3,534,006 shares changing hands. The stock had previously closed at $13.90.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings upgraded Organon & Co. from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Four investment analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Organon & Co. presently has an average rating of “Reduce” and a consensus price target of $12.00.
Get Our Latest Report on Organon & Co.
Organon & Co. Stock Performance
The stock’s 50-day simple moving average is $13.76 and its two-hundred day simple moving average is $11.71. The stock has a market cap of $3.65 billion, a price-to-earnings ratio of 18.30, a price-to-earnings-growth ratio of 1.28 and a beta of 1.53. The company has a debt-to-equity ratio of 7.11, a quick ratio of 1.51 and a current ratio of 2.02.
Organon & Co. (NYSE:OGN – Get Free Report) last released its earnings results on Friday, October 30th. The company reported $0.94 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.06. Organon & Co. had a return on equity of 82.06% and a net margin of 3.49%. The firm had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.58 billion. Analysts forecast that Organon & Co. will post 3.24 earnings per share for the current year.
Organon & Co. Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Monday, November 9th will be paid a dividend of $0.02 per share. This represents a $0.08 annualized dividend and a yield of 0.6%. The ex-dividend date is Monday, November 9th. Organon & Co.’s payout ratio is currently 10.53%.
Hedge Funds Weigh In On Organon & Co.
Hedge funds have recently made changes to their positions in the business. Allied Private Wealth LLC bought a new position in Organon & Co. during the second quarter worth about $33,000. Nykredit A S acquired a new position in shares of Organon & Co. in the 2nd quarter worth approximately $76,000. GAMMA Investing LLC grew its holdings in shares of Organon & Co. by 69.8% during the second quarter. GAMMA Investing LLC now owns 5,782 shares of the company’s stock worth $78,000 after purchasing an additional 2,376 shares during the last quarter. Steward Partners Investment Advisory LLC increased its stake in shares of Organon & Co. by 18.4% in the third quarter. Steward Partners Investment Advisory LLC now owns 8,877 shares of the company’s stock valued at $122,000 after buying an additional 1,379 shares in the last quarter. Finally, Wedmont Private Capital bought a new position in shares of Organon & Co. in the second quarter worth about $136,000. Institutional investors and hedge funds own 77.43% of the company’s stock.
Organon & Co. Company Profile
Organon & Co. is a global health care company focused on women’s health, biosimilars and established medicines. It develops and markets prescription medicines and other health products for patients and health care professionals. Its women’s health portfolio includes contraceptive and fertility products, while its biosimilars business offers biologic medicines in areas such as immunology and oncology. The company also sells established medicines across several therapeutic areas, including cardiovascular health, respiratory conditions and dermatology.
Featured Stories
- Five stocks we like better than Organon & Co.
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
